Ligand Pharmaceuticals LGND Proceeds from Maturities, Prepayments and Calls of Short-Term Investments
Proceeds from Maturities, Prepayments and Calls of Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's proceeds from maturities, prepayments and calls of short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's proceeds from maturities, prepayments and calls of short-term investments?
- Ligand Pharmaceuticals (LGND) reported proceeds from maturities, prepayments and calls of short-term investments of $119.35M in Q1 2026.
- How has Ligand Pharmaceuticals's proceeds from maturities, prepayments and calls of short-term investments changed year-over-year?
- Ligand Pharmaceuticals's proceeds from maturities, prepayments and calls of short-term investments increased by 268.8% year-over-year, from $32.36M to $119.35M.
- What is the long-term trend for Ligand Pharmaceuticals's proceeds from maturities, prepayments and calls of short-term investments?
- Over 3 years (2021 to 2025), Ligand Pharmaceuticals's proceeds from maturities, prepayments and calls of short-term investments has grown at a 48.0% compound annual growth rate (CAGR), from $67.11M to $217.7M.